Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 17/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30298607 | 0.89 | SLC34A1 (0.51) | SLC34A1CYP17A1SPR | |
| SCHEMBL20075445 | 0.89 | SLC34A1 (0.51) | SLC34A1CYP17A1SPR | |
| SCHEMBL20074787 | 0.82 | SLC34A1 (0.54) | SLC34A1 | |
| SCHEMBL20074696 | 0.74 | L3MBTL1 (0.45) | SLC34A1SPR | |
| SCHEMBL20074751 | 0.74 | SLC34A1 (0.50) | SLC34A1 | |
| SCHEMBL20075227 | 0.73 | SLC34A1 (0.42) | SLC34A1 | |
| SCHEMBL20074682 | 0.70 | SLC34A1 (0.52) | SLC34A1 | |
| SCHEMBL20075158 | 0.68 | SLC34A1 (0.49) | SLC34A1 | |
| SCHEMBL20075226 | 0.68 | SLC34A1 (0.40) | SLC34A1 | |
| SCHEMBL20074933 | 0.68 | SLC34A1 (0.39) | SLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| WO-2018069222-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | REN, ATP6V1B1, GLS | SLC34A1 1550/4885CYP17A1 2044/4885ELANE 2103/4885 |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | SLC34A1 1550/4885CYP17A1 2044/4885ELANE 2103/4885 |
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | SLC34A1 1550/4885CYP17A1 2044/4885ELANE 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.